Preclinical data indicate that rifaximin could be repurposed as a novel strategy for preventing and reducing the severity of gastrointestinal damage, particularly diarrhea, that results from pelvic irradiation. So, The aim of the work is to investigate the impact of Rifaximin on the incidence and severity of radiotherapy-induced diarrhea in cancer patients undergoing pelvic irradiation with or without chemotherapy.
Individuals who are 18 years of age or older and have been diagnosed with non metastatic pelvic cancers.
Patients who are undergoing curative intent radiotherapy with or without chemotherapy treatment.
Patients who have a record of intestinal resection in their medical history.
Patients with a medical background of irritable bowel syndrome.
Patients with a history of inflammatory bowel disease.
Patients who regularly take anti-diarrheal medications before commencing radiotherapy.
Parallel
Rifaximin 550 MG
DrugOral Rifaximin 550mg twice daily from the start of pelvic radiotherapy, with or without chemotherapy, as a preventive measure, and continuing every day until the end of the treatment up to 5 to seven weeks.
Standard Care Chemoradiation
DrugPatients will receive standard chemotherapy and/or radiation
The difference in the incidence and severity of radiotherapy induced diarrhea grade 2 or more according to Common Terminology Criteria for Adverse Events (CTCAE)in cancer patients undergo pelvic irradiation.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
